9/24/20 Leaderboard Pharma

MVASI Bevacizumab-awwb Syringes

Available from Edge Pharma

MVASI™ Bevacizumab-awwb, which was approved by the FDA in 2017, is now available in the United States. It is a new biosimilar to Avastin® that is widely used off-label in ophthalmology. Compliance and convenience are now possible with Edge Pharma's unit dose MVASI™ Bevacizumab-awwb syringes.

Rate and Review Edge Pharma

Rating: 0 - 0 reviews
Let users know what you would have wanted to know about this company.
Click on a star to rate this company
  Privacy Policy.
When writing a review, please adhere to the Review Guidelines.